Related Experiment Videos
Splenic phagocytic function in children with sickle cell anemia receiving long-term hypertransfusion therapy
G R Buchanan1, V McKie, E A Jackson
1Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas 75235-9063.
The Journal of Pediatrics
|October 1, 1989
Summary
Intensive blood transfusions in sickle cell anemia patients preserve splenic function. Less intensive therapy can lead to abnormal spleen function, but this may be reversible with hypertransfusion therapy.
Area of Science:
- Hematology
- Pediatric Medicine
- Immunology
Background:
- Sickle cell anemia (SCA) is a genetic blood disorder.
- Splenic dysfunction is common in SCA patients, increasing infection risk.
- Blood transfusions are a primary treatment for SCA complications like cerebrovascular accidents.
Purpose of the Study:
- To investigate the impact of different blood transfusion protocols on splenic function in pediatric SCA patients.
- To determine if intensive transfusion therapy can prevent or reverse splenic dysfunction.
Main Methods:
- Assessed splenic function using radionuclide scans and pocked erythrocyte counts in 12 SCA patients (ages 6-18) with a history of cerebrovascular accidents.
- Compared outcomes between patients receiving intensive transfusion therapy (hemoglobin S <20%) and less intensive therapy (hemoglobin S 30-40%).
Main Results:
- Five patients on intensive transfusion therapy maintained normal or increased splenic size and function.
- Seven patients on less intensive therapy exhibited abnormal splenic function (absent radionuclide uptake, elevated pocked erythrocyte count).
- No patients on intensive therapy developed bacterial septicemia.
Conclusions:
- Splenic function in SCA patients on long-term transfusion therapy is variable and depends on transfusion intensity.
- Intensive transfusion therapy appears to preserve splenic function and may prevent septicemia.
- Splenic involution and fibrosis in SCA may be reversible with appropriate transfusion management.